Yangtze River won 5 blockbuster new products in one fell swoop to impact Renfu's exclusive painkillers

Recently, Yangtze River’s product pipeline has been continuously updated: 3 types of generic drug nalbuphine hydrochloride injection have entered the administrative approval stage, and this product is currently only sold by Renfu; 5 generic drugs have been approved for marketing, and 4 of them have been approved for production and deemed to have been used.

Source: official website of the State Food and Drug Administration

Nalbuphine hydrochloride belongs to the κ receptor agonist/μ receptor partial antagonistic analgesic.

At present, only Renfu Pharmaceutical's nalbuphine hydrochloride injection is on the market in China.

Yangtze River's recently approved varieties

Source: official website of the State Food and Drug Administration

Ornithine aspartate injection is a six-category generic drug.

Bortezomib for injection, azithromycin for injection, linagliptin tablets, and voriconazole tablets have been approved for production and are deemed to have been reviewed.

According to data from Meinenet, currently 65 varieties of Yangzijiang Pharmaceutical have passed or deemed to have passed the consistency evaluation, and 13 varieties have been included in the fifth batch of centralized procurement, of which 12 are injections.

From the perspective of competition, the competition for oral regular-release formulations of rivaroxaban is the most intense.

From the perspective of the competition pattern of end products in China’s public medical institutions in 2020, Yangtze River’s expertise in Thymus Actin Injection, Azithromycin Injection, Ceftazidime Injection, Lansoprazole Injection, Fasudil Injection, Rivaroxaban Oral Constant Release Formulation, Fluconazole Sodium chloride injections account for less than 1% of the market.

Source: Mi Neiwang database, State Food and Drug Administration